Wells Fargo’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.37M | Buy |
44,807
+31,020
| +225% | +$2.71M | ﹤0.01% | 2966 |
|
|
2026
Q1 | $1.16M | Sell |
13,787
-15,181
| -52% | -$879K | ﹤0.01% | 3658 |
|
|
2025
Q4 | $1.19M | Buy |
28,968
+16,585
| +134% | +$643K | ﹤0.01% | 3834 |
|
|
2025
Q3 | $487K | Buy |
12,383
+57
| +0.5% | +$1.46K | ﹤0.01% | 4323 |
|
|
2025
Q2 | $230K | Sell |
12,326
-3,053
| -20% | -$57.3K | ﹤0.01% | 4696 |
|
|
2025
Q1 | $279K | Buy |
15,379
+1,561
| +11% | +$34.4K | ﹤0.01% | 4470 |
|
|
2024
Q4 | $301K | Sell |
13,818
-8,271
| -37% | -$213K | ﹤0.01% | 4521 |
|
|
2024
Q3 | $605K | Buy |
22,089
+11,770
| +114% | +$328K | ﹤0.01% | 3871 |
|
|
2024
Q2 | $267K | Buy |
10,319
+10,095
| +4,507% | +$243K | ﹤0.01% | 4319 |
|
|
2024
Q1 | $6.72K | Buy |
224
+150
| +203% | +$3.26K | ﹤0.01% | 5835 |
|
|
2023
Q4 | $769 | Buy |
74
+24
| +48% | +$265 | ﹤0.01% | 6290 |
|
|
2023
Q3 | $684 | Buy |
50
+1
| +2% | +$13 | ﹤0.01% | 6292 |
|
|
2023
Q2 | $591 | Buy |
49
+1
| +2% | +$11 | ﹤0.01% | 6451 |
|
|
2023
Q1 | $608 | Hold |
48
| – | – | ﹤0.01% | 6505 |
|
|
2022
Q4 | $300 | Sell |
48
-92
| -66% | -$1.63K | ﹤0.01% | 6509 |
|
|
2022
Q3 | $3K | Sell |
140
-210
| -60% | -$5.75K | ﹤0.01% | 6042 |
|
|
2022
Q2 | $7K | Buy |
350
+244
| +230% | +$6.03K | ﹤0.01% | 5879 |
|
|
2022
Q1 | $5K | Sell |
106
-663
| -86% | -$36.2K | ﹤0.01% | 6467 |
|
|
2021
Q4 | $54K | Sell |
769
-972
| -56% | -$97.7K | ﹤0.01% | 5932 |
|
|
2021
Q3 | $203K | Buy |
1,741
+1,712
| +5,903% | +$199K | ﹤0.01% | 5085 |
|
|
2021
Q2 | $4K | Sell |
29
-133
| -82% | -$24.4K | ﹤0.01% | 6391 |
|
|
2021
Q1 | $30K | Sell |
162
-975
| -86% | -$164K | ﹤0.01% | 6031 |
|
|
2020
Q4 | $143K | Buy |
1,137
+394
| +53% | +$44.7K | ﹤0.01% | 5215 |
|
|
2020
Q3 | $81K | Sell |
743
-1
| -0.1% | -$118 | ﹤0.01% | 5339 |
|
|
2020
Q2 | $89K | Sell |
744
-469
| -39% | -$66.1K | ﹤0.01% | 5272 |
|
|
2020
Q1 | $122K | Sell |
1,213
-46
| -4% | -$8.52K | ﹤0.01% | 4960 |
|
|
2019
Q4 | $306K | Sell |
1,259
-882
| -41% | -$165K | ﹤0.01% | 4713 |
|
|
2019
Q3 | $352K | Buy |
2,141
+265
| +14% | +$50.3K | ﹤0.01% | 4608 |
|
|
2019
Q2 | $443K | Buy |
1,876
+1,345
| +253% | +$333K | ﹤0.01% | 4457 |
|
|
2019
Q1 | $140K | Buy |
531
+493
| +1,297% | +$85.1K | ﹤0.01% | 4996 |
|
|
2018
Q4 | $3K | Buy |
38
+2
| +6% | +$273 | ﹤0.01% | 6137 |
|
|
2018
Q3 | $7K | Buy |
+36
| New | +$7.58K | ﹤0.01% | 6055 |
|
Other funds holding DNTH
FFM
APM
OCA
Wells Fargo's DNTH Position: Q2 2026 in Review
Wells Fargo increased its Dianthus Therapeutics (DNTH) stake by 225% in Q2 2026, buying an estimated $2.71M and bringing the position to 44,807 shares worth $4.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2966.
Wells Fargo first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Wells Fargo held 44,807 shares of Dianthus Therapeutics worth $4.37M as of Q2 2026.
- Wells Fargo bought 31,020 Dianthus Therapeutics shares in Q2 2026, an estimated $2.71M.
- Dianthus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2966 holding.
- Wells Fargo first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.